Puma Biotechnology Launches ALISCA™-Breast1 Phase II Trial of Alisertib in HR+/HER2- Metastatic Breast Cancer

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has announced the launch of its ALISCA™-Breast1 Phase II trial (PUMA-ALI-1201; NCT06369285). The study will evaluate alisertib, in combination with endocrine therapy,…

Read MorePuma Biotechnology Launches ALISCA™-Breast1 Phase II Trial of Alisertib in HR+/HER2- Metastatic Breast Cancer